DGAP-News: Biotest AG / Key word(s): Research Update
05.12.2017 / 07:00
The issuer is solely responsible for the content of this announcement.
Biotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University
– Trial investigates personalized treatment approaches with Biotest’s Pentaglobin(R) in patients with abdominal inflammation (peritonitis)
– Novel testing systems included to determine individual patient risks
Dreieich, 5 December 2017. Today, the first patient was enrolled in the PEPPER trial. Biotest supports the trial on personalized medicine with Pentaglobin(R) after control of the inflammation source in peritonitis patients (PEPPER trial). It is designed to investigate in 200 patients strategies to personalize immuno-modulating approaches in patients with postoperative secondary peritonitis. With an overall mortality of more than 30%, peritonitis is one of the most fatal diseases on intensive care units.
Prof Gernot Marx from the Aachen University (RWTH Aachen), the coordinating investigator of the study mentioned “Sepsis or even peritonitis with an abdominal focus is such a heterogeneous syndrome that new and more individualized treatments are needed. An aim of the study is to identify which patient needs which kind of treatment with the immuno-modulatory substance Pentaglobin(R). Currently we only have well established antibiotics and surgical interventions to combat the disastrous systemic infections and subsequent inflammation. Personalized treatments to normalize the immune response and to overcome the inflammatory dysregulation are urgently needed.”
The subgroups identified in the PEPPER trial will enable physicians to better understand how to use immuno-modulatory treatment in this particular patient group. Results from this trial can be an important step towards a more personalized and hence successful treatment of peritonitis. The trial has been approved by the Ethics Committee at Aachen University and by Paul Ehrlich Institute (PEI) in Germany.
Further partners in the trial are Curetis GmbH for molecular diagnostic analysis and Sphingotec GmbH for the determination of additional diagnostic parameters.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
05.12.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|